Quantum Dots: Heralding a Brighter Future for Clinical Diagnostics

Tamer M Samir; Mai MH Mansour; Steven C Kazmierczak; Hassan ME Azzazy


Nanomedicine. 2012;7(11):1755-1769. 

In This Article

Future Perspective

The coming few years are likely to see QDs making a distinct improvement in the field of clinical laboratory medicine. QDs have the potential to be much more than just better fluorophores and could open up new frontiers beyond conventional testing strategies. The remarkable developments in other nanostructures have further expanded the realm of analytical strategies utilizing QDs. For example, a FRET-based assay for H5N1 influenza virus has been developed using QDs and carbon nanotubes.[63] QDs have been used for simultaneous monitoring of a drug used for the treatment of colorectal cancer and the corresponding cancer biomarker. Thus, this allows assessment of the therapeutic effect of the drug on the cancer, opening a new arena of quantitative pharmacological and pharmacotherapeutic assays in which both the drug and its effect can be quantitatively measured.[64] Additionally, QD-peptide conjugates have been used for multiplex detection of two enzymes of different classes, a protease and kinase, in a FRET-based assay, demonstrating significant utility for drug screening and diagnosis.[65] QDs also show promise in supporting point-of-care testing. They have been used in a lateral flow strip format for the development of a portable biosensor for detecting nitrated ceruloplasmin as a marker of a cardiovascular disease, with detection limit of 8 ng/ml.[66]